266 related articles for article (PubMed ID: 32006900)
1. The role of PPM1D in cancer and advances in studies of its inhibitors.
Deng W; Li J; Dorrah K; Jimenez-Tapia D; Arriaga B; Hao Q; Cao W; Gao Z; Vadgama J; Wu Y
Biomed Pharmacother; 2020 May; 125():109956. PubMed ID: 32006900
[TBL] [Abstract][Full Text] [Related]
2. Chemical Inhibition of Wild-Type p53-Induced Phosphatase 1 (WIP1/PPM1D) by GSK2830371 Potentiates the Sensitivity to MDM2 Inhibitors in a p53-Dependent Manner.
Esfandiari A; Hawthorne TA; Nakjang S; Lunec J
Mol Cancer Ther; 2016 Mar; 15(3):379-91. PubMed ID: 26832796
[TBL] [Abstract][Full Text] [Related]
3. PPM1D is a potential prognostic biomarker and correlates with immune cell infiltration in hepatocellular carcinoma.
Yu Z; Song Y; Cai M; Jiang B; Zhang Z; Wang L; Jiang Y; Zou L; Liu X; Yu N; Mao X; Peng C; Liu S
Aging (Albany NY); 2021 Sep; 13(17):21294-21308. PubMed ID: 34470916
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of WIP1 phosphatase sensitizes breast cancer cells to genotoxic stress and to MDM2 antagonist nutlin-3.
Pechackova S; Burdova K; Benada J; Kleiblova P; Jenikova G; Macurek L
Oncotarget; 2016 Mar; 7(12):14458-75. PubMed ID: 26883108
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of Ser/Thr phosphatase PPM1D induces neutrophil differentiation in HL-60 cells.
Kamada R; Kudoh F; Yoshimura F; Tanino K; Sakaguchi K
J Biochem; 2017 Oct; 162(4):303-308. PubMed ID: 28486685
[TBL] [Abstract][Full Text] [Related]
6. Clinical Significance of the Wild Type p53-Induced Phosphatase 1 Expression in Invasive Breast Cancer.
Inoue Y; Yamashita N; Kitao H; Tanaka K; Saeki H; Oki E; Oda Y; Tokunaga E; Maehara Y
Clin Breast Cancer; 2018 Aug; 18(4):e643-e650. PubMed ID: 29275106
[TBL] [Abstract][Full Text] [Related]
7. Cooperation of Nutlin-3a and a Wip1 inhibitor to induce p53 activity.
Sriraman A; Radovanovic M; Wienken M; Najafova Z; Li Y; Dobbelstein M
Oncotarget; 2016 May; 7(22):31623-38. PubMed ID: 27183917
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of mutant PPM1D enhances DNA damage response and growth suppressive effects of ionizing radiation in diffuse intrinsic pontine glioma.
Akamandisa MP; Nie K; Nahta R; Hambardzumyan D; Castellino RC
Neuro Oncol; 2019 Jun; 21(6):786-799. PubMed ID: 30852603
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of protein phosphatase PPM1D enhances retinoic acid-induced differentiation in human embryonic carcinoma cell line.
Ogasawara S; Chuman Y; Michiba T; Kamada R; Imagawa T; Sakaguchi K
J Biochem; 2019 Jun; 165(6):471-477. PubMed ID: 30576481
[TBL] [Abstract][Full Text] [Related]
10. WIP1 phosphatase as pharmacological target in cancer therapy.
Pecháčková S; Burdová K; Macurek L
J Mol Med (Berl); 2017 Jun; 95(6):589-599. PubMed ID: 28439615
[TBL] [Abstract][Full Text] [Related]
11. Wip1: A candidate phosphatase for cancer diagnosis and treatment.
Oghabi Bakhshaiesh T; Majidzadeh-A K; Esmaeili R
DNA Repair (Amst); 2017 Jun; 54():63-66. PubMed ID: 28385459
[TBL] [Abstract][Full Text] [Related]
12. Protein phosphatase, Mg
Husby S; Hjermind Justesen E; Grønbæk K
Br J Haematol; 2021 Feb; 192(4):697-705. PubMed ID: 33616916
[TBL] [Abstract][Full Text] [Related]
13. Phosphatase magnesium-dependent 1 δ (PPM1D), serine/threonine protein phosphatase and novel pharmacological target in cancer.
Nahta R; Castellino RC
Biochem Pharmacol; 2021 Feb; 184():114362. PubMed ID: 33309518
[TBL] [Abstract][Full Text] [Related]
14. Novel inhibitors targeting PPM1D phosphatase potently suppress cancer cell proliferation.
Ogasawara S; Kiyota Y; Chuman Y; Kowata A; Yoshimura F; Tanino K; Kamada R; Sakaguchi K
Bioorg Med Chem; 2015 Oct; 23(19):6246-9. PubMed ID: 26358280
[TBL] [Abstract][Full Text] [Related]
15. A small molecule inhibitor of p53-inducible protein phosphatase PPM1D.
Yagi H; Chuman Y; Kozakai Y; Imagawa T; Takahashi Y; Yoshimura F; Tanino K; Sakaguchi K
Bioorg Med Chem Lett; 2012 Jan; 22(1):729-32. PubMed ID: 22115592
[TBL] [Abstract][Full Text] [Related]
16. Allosteric inhibition of PPM1D serine/threonine phosphatase via an altered conformational state.
Miller PG; Sathappa M; Moroco JA; Jiang W; Qian Y; Iqbal S; Guo Q; Giacomelli AO; Shaw S; Vernier C; Bajrami B; Yang X; Raffier C; Sperling AS; Gibson CJ; Kahn J; Jin C; Ranaghan M; Caliman A; Brousseau M; Fischer ES; Lintner R; Piccioni F; Campbell AJ; Root DE; Garvie CW; Ebert BL
Nat Commun; 2022 Jun; 13(1):3778. PubMed ID: 35773251
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of the DNA damage response phosphatase PPM1D reprograms neutrophils to enhance anti-tumor immune responses.
Uyanik B; Goloudina AR; Akbarali A; Grigorash BB; Petukhov AV; Singhal S; Eruslanov E; Chaloyard J; Lagorgette L; Hadi T; Baidyuk EV; Sakai H; Tessarollo L; Ryffel B; Mazur SJ; Lirussi F; Garrido C; Appella E; Demidov ON
Nat Commun; 2021 Jun; 12(1):3622. PubMed ID: 34131120
[TBL] [Abstract][Full Text] [Related]
18. Reversal of the ATM/ATR-mediated DNA damage response by the oncogenic phosphatase PPM1D.
Lu X; Nguyen TA; Donehower LA
Cell Cycle; 2005 Aug; 4(8):1060-4. PubMed ID: 15970689
[TBL] [Abstract][Full Text] [Related]
19. Chemical Features Important for Activity in a Class of Inhibitors Targeting the Wip1 Flap Subdomain.
Tagad HD; Debnath S; Clausse V; Saha M; Mazur SJ; Appella E; Appella DH
ChemMedChem; 2018 May; 13(9):894-901. PubMed ID: 29476592
[TBL] [Abstract][Full Text] [Related]
20. Gain-of-function mutations of PPM1D/Wip1 impair the p53-dependent G1 checkpoint.
Kleiblova P; Shaltiel IA; Benada J; Ševčík J; Pecháčková S; Pohlreich P; Voest EE; Dundr P; Bartek J; Kleibl Z; Medema RH; Macurek L
J Cell Biol; 2013 May; 201(4):511-21. PubMed ID: 23649806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
